TARRYTOWN, N.Y. - The European Commission has granted approval to Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) for Ordspono™ (odronextamab), marking the first regulatory nod for the bispecific antibody designed to treat adult patients with relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma post two or more lines of systemic therapy.
This approval provides a new treatment option for these lymphoma subtypes, which are among the most common forms of non-Hodgkin lymphoma. Follicular lymphoma is an incurable disease that often relapses after initial treatment, and diffuse large B-cell lymphoma is an aggressive subtype where up to half of high-risk patients see their disease progress after first-line treatment.
Ordspono functions by connecting the lymphoma cell to a killer T cell, facilitating the destruction of the cancer cell. Clinical trials, including the Phase 1 ELM-1 and Phase 2 ELM-2, showed promising results, with high response rates in patients, some achieving complete remission. Notably, in the ELM-2 trial, 80% of follicular lymphoma patients responded to the treatment, with 73% achieving complete remission.
However, the treatment comes with a risk of adverse reactions such as cytokine release syndrome and serious infections, which can be fatal. The development of Ordspono is part of Regeneron's ongoing commitment to advance a portfolio of treatments for oncology and other diseases, leveraging its bispecific antibody platform.
The company is also conducting the OLYMPIA program, which includes multiple Phase 3 trials investigating Ordspono as a monotherapy and in combination with other treatments in earlier lines of therapy. These efforts represent a broader strategy to explore the potential of bispecific antibodies in treating hematologic cancers and solid tumors.
Ordspono's approval is a significant milestone for Regeneron, reflecting the company's dedication to addressing unmet medical needs in the field of hematology. The approval is based on the press release statement from Regeneron Pharmaceuticals, Inc.
In other recent news, Regeneron Pharmaceuticals has seen a series of significant developments. Piper Sandler raised the company's stock price target to $1,242 from $1,166, maintaining an Overweight rating. This adjustment is based on stable expectations for Regeneron's Dupixent, despite potential competition from Galderma's newly approved drug, Nemluvio.
Simultaneously, TD Cowen reaffirmed a Buy rating for Regeneron, expressing confidence in the ongoing success of the Eylea franchise and the potential growth of Eylea HD. The recent approval of Dupixent for treating Chronic Obstructive Pulmonary Disease (COPD) is seen as a significant market opportunity.
Regeneron reported a 12% increase in total revenues to $3.55 billion in the second quarter of 2024. This was driven by strong product sales, including Eylea HD sales in the U.S. maintaining a 45% market share with $304 million in earnings, while Dupixent global revenues surged by 29% to $3.56 billion.
Despite these promising financial results, Regeneron anticipates a potential delay in FDA approval for its linvoseltamab treatment and is currently undergoing a DOJ investigation into its marketing practices for Eylea. However, CEO Leonard Schleifer has expressed plans for the early 2025 launch of Vabysmo, and President Marion McCourt reported positive launch progress for Eylea HD, particularly among treatment-naive patients.
Finally, Regeneron has adjusted its full-year 2024 financial guidance, now expecting a gross margin of approximately 89%. These are among the recent developments in the company's ongoing journey.
InvestingPro Insights
As Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) celebrates the European Commission's approval of Ordspono™, their financial metrics and market performance offer additional insights into the company's standing. With a robust market capitalization of $129.43 billion and a Price/Earnings (P/E) ratio of 29.75, Regeneron showcases its significance in the biotechnology industry. This P/E ratio has remained stable over the last twelve months as of Q2 2024, indicating market confidence in the company's earnings potential.
Regeneron's financial health is further underscored by a Price/Book ratio of 4.59 and a Gross Profit Margin of 53.27%, reflecting the company's ability to generate earnings relative to shareholder equity and sales, respectively. Moreover, the company's solid gross profit of $7.19 billion over the last twelve months reinforces its financial stability.
InvestingPro Tips highlight that Regeneron is a prominent player in the Biotechnology industry, operating with a moderate level of debt and possessing liquid assets that exceed short-term obligations. These factors contribute to the company's resilience and its capacity to navigate the competitive landscape. Additionally, the stock's low price volatility suggests a stable investment, while its position near the 52-week high underscores recent positive performance.
For investors seeking more comprehensive analysis, there are numerous additional InvestingPro Tips available on the platform, including insights into earnings revisions, return on assets, and analyst profitability predictions for Regeneron. These tips can provide valuable guidance for making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.